Related Experiment Video
Updated: Dec 25, 2025
07:35
Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
Published on: July 8, 2025
931
Pregabalin-induced sexual disinhibition
R Murphy1,2, D McGuinness2, B Hallahan1,2
1School of Medicine, College of Medicine Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland.
Irish Journal of Psychological Medicine
|April 1, 2020
Summary
Pregabalin, used for anxiety, can cause sexual side effects like disinhibition and increased libido. These effects may be managed by reducing the pregabalin dose.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Pregabalin, a gamma-aminobutyric acid (GABA) analogue, is commonly prescribed for anxiety and neuropathic pain.
- Sexual side effects are infrequently reported with pregabalin treatment.
Observation:
- A 27-year-old male with recurrent depressive disorder experienced acute sexual disinhibition and increased libido.
- These adverse sexual effects emerged during pregabalin therapy for anxiety symptoms.
Findings:
- The patient's sexual side effects were temporally associated with pregabalin use.
- A reduction in pregabalin dosage led to a decrease in the observed adverse sexual effects.
Implications:
- This case highlights a rare but significant association between pregabalin and sexual disinhibition.
- Increased clinical awareness can facilitate earlier management, potentially through dose adjustment rather than discontinuation.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
539
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
539
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
424
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
424
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.1K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
142
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
142
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
810
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
810
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
541
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
541